A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo

In vivo genome editing using Staphylococcus aureus Cas9

Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687

Biology and Applications of CRISPR Systems: Harnessing Nature’s Toolbox for Genome Engineering

Wright, A. V., Nuñez, J. K., & Doudna, J. A. (2016) · Cell · doi:10.1016/j.cell.2015.12.035 · Cited by 989

HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B

Nassal, M. (2015) · Gut · doi:10.1136/gutjnl-2015-309809 · Cited by 932

Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo

Yin, H., Song, C.-Q., Dorkin, J. R., Zhu, L. J., Li, Y., Wu, Q., Park, A., Yang, J., Suresh, S., Bizhanova, A., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3471 · Cited by 876

The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo

Lin, S.-R., Yang, H.-C., Kuo, Y.-T., Liu, C.-J., Yang, T.-Y., Sung, K.-C., Lin, Y.-Y., Wang, H.-Y., Wang, C.-C., Shen, Y.-C., et al. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.38 · Cited by 386

Hydrodynamic injection of viral DNA: A mouse model of acute hepatitis B virus infection

Yang, P. L., Althage, A., Chung, J., & Chisari, F. V. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202398599 · Cited by 381

CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus

Ramanan, V., Shlomai, A., Cox, D. B. T., Schwartz, R. E., Michailidis, E., Bhatta, A., Scott, D. A., Zhang, F., Rice, C. M., & Bhatia, S. N. (2015) · Scientific Reports · doi:10.1038/srep10833 · Cited by 312

An Orthogonal Array Optimization of Lipid-like Nanoparticles for mRNA Delivery in Vivo

Li, B., Luo, X., Deng, B., Wang, J., McComb, D. W., Shi, Y., Gaensler, K. M. L., Tan, X., Dunn, A. L., Kerlin, B. A., et al. (2015) · Nano Letters · doi:10.1021/acs.nanolett.5b03528 · Cited by 261

Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication

Dong, C., Qu, L., Wang, H., Wei, L., Dong, Y., & Xiong, S. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.03.015 · Cited by 245

Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus

Zhen, S., Hua, L., Liu, Y.-H., Gao, L.-C., Fu, J., Wan, D.-Y., Dong, L.-H., Song, H.-F., & Gao, X. (2015) · Gene Therapy · doi:10.1038/gt.2015.2 · Cited by 215

Lipid nanoparticles for mRNA delivery

Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076

Drug delivery systems for RNA therapeutics

Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349

Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery

Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127

A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing

Finn, J. D., Smith, A. R., Patel, M. C., Shaw, L., Youniss, M. R., van Heteren, J., Dirstine, T., Ciullo, C., Lescarbeau, R., Seitzer, J., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.014 · Cited by 878

Tools for translation: non-viral materials for therapeutic mRNA delivery

Hajj, K. A., & Whitehead, K. A. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.56 · Cited by 799

CRISPR/Cas9 therapeutics: progress and prospects

Li, T., Yang, Y., Qi, H., Cui, W., Zhang, L., Fu, X., He, X., Liu, M., Li, P., & Yu, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01309-7 · Cited by 824

Exosome–Liposome Hybrid Nanoparticles Deliver CRISPR/Cas9 System in MSCs

Lin, Y., Wu, J., Gu, W., Huang, Y., Tong, Z., Huang, L., & Tan, J. (2018) · Advanced Science · doi:10.1002/advs.201700611 · Cited by 625

Therapeutic in vivo delivery of gene editing agents

Raguram, A., Banskota, S., & Liu, D. R. (2022) · Cell · doi:10.1016/j.cell.2022.03.045 · Cited by 552

Self-assembled mRNA vaccines

Kim, J., Eygeris, Y., Gupta, M., & Sahay, G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.014 · Cited by 514

A Comprehensive Review of mRNA Vaccines

Gote, V., Bolla, P. K., Kommineni, N., Butreddy, A., Nukala, P. K., Palakurthi, S. S., & Khan, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032700 · Cited by 457

Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities

Li, L., Hu, S., & Chen, X. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.04.031 · Cited by 415

The challenge and prospect of mRNA therapeutics landscape

Weng, Y., Li, C., Yang, T., Hu, B., Zhang, M., Guo, S., Xiao, H., Liang, X.-J., & Huang, Y. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107534 · Cited by 417

Thermo-triggered release of CRISPR-Cas9 system by lipid-encapsulated gold nanoparticles for tumor therapy

Wang, P., Zhang, L., Zheng, W., Cong, L., Guo, Z., Xie, Y., Wang, L., Tang, R., Feng, Q., Hamada, Y., et al. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201708689 · Cited by 410

Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3

Qiu, M., Glass, Z., Chen, J., Haas, M., Jin, X., Zhao, X., Rui, X., Ye, Z., Li, Y., Zhang, F., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2020401118 · Cited by 423

Fast and Efficient CRISPR/Cas9 Genome Editing In Vivo Enabled by Bioreducible Lipid and Messenger RNA Nanoparticles

Liu, J., Chang, J., Jiang, Y., Meng, X., Sun, T., Mao, L., Xu, Q., & Wang, M. (2019) · Advanced Materials · doi:10.1002/adma.201902575 · Cited by 373

Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery

Maeki, M., Uno, S., Niwa, A., Okada, Y., & Tokeshi, M. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.017 · Cited by 359

Engineering the delivery system for CRISPR-based genome editing

Glass, Z., Lee, M., Li, Y., & Xu, Q. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2017.11.006 · Cited by 345

CRISPR/Cas9 for cancer research and therapy

Zhan, T., Rindtorff, N., Betge, J., Ebert, M., & Boutros, M. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.04.001 · Cited by 338

High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing

Sago, C. D., Lokugamage, M. P., Paunovska, K., Vanover, D. A., Monaco, C. M., Shah, N. N., Gamboa Castro, M., Anderson, S. E., Rudoltz, T. G., Lando, G. N., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1811276115 · Cited by 313

Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53 -deficient cancers to mTOR inhibition

Kong, N., Tao, W., Ling, X., Wang, J., Xiao, Y., Shi, S., Ji, X., Shajii, A., Gan, S. T., Kim, N. Y., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw1565 · Cited by 314

Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice

Kenjo, E., Hozumi, H., Makita, Y., Iwabuchi, K. A., Fujimoto, N., Matsumoto, S., Kimura, M., Amano, Y., Ifuku, M., Naoe, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26714-w · Cited by 313

Targeted Delivery of CRISPR/Cas9‐Mediated Cancer Gene Therapy via Liposome‐Templated Hydrogel Nanoparticles

Chen, Z., Liu, F., Chen, Y., Liu, J., Wang, X., Chen, A. T., Deng, G., Zhang, H., Liu, J., Hong, Z., et al. (2017) · Advanced Functional Materials · doi:10.1002/adfm.201703036 · Cited by 297

CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases

Sharma, G., Sharma, A. R., Bhattacharya, M., Lee, S., & Chakraborty, C. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.028 · Cited by 310

In vivo gene delivery mediated by non-viral vectors for cancer therapy

Mohammadinejad, R., Dehshahri, A., Madamsetty, V. S., Zahmatkeshan, M., Tavakol, S., Makvandi, P., Khorsandi, D., Pardakhty, A., Ashrafizadeh, M., Afshar, E. G., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.06.038 · Cited by 239

Macrophage-Specific in Vivo Gene Editing Using Cationic Lipid-Assisted Polymeric Nanoparticles

Luo, Y., Xu, C., Li, H., Cao, Z., Liu, J., Wang, J., Du, X., Yang, X., Gu, Z., & Wang, J. (2018) · ACS Nano · doi:10.1021/acsnano.7b07874 · Cited by 223

Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma

Liang, C., Li, F., Wang, L., Zhang, Z., Wang, C., He, B., Li, J., Chen, Z., Shaikh, A. B., Liu, J., et al. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.09.015 · Cited by 217

Genome Editing for Cancer Therapy: Delivery of Cas9 Protein/sgRNA Plasmid via a Gold Nanocluster/Lipid Core–Shell Nanocarrier

Wang, P., Zhang, L., Xie, Y., Wang, N., Tang, R., Zheng, W., & Jiang, X. (2017) · Advanced Science · doi:10.1002/advs.201700175 · Cited by 215

Engineered materials for in vivo delivery of genome-editing machinery

Tong, S., Moyo, B., Lee, C. M., Leong, K. W., & Bao, G. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0145-9 · Cited by 208

Nanoparticles Containing Oxidized Cholesterol Deliver mRNA to the Liver Microenvironment at Clinically Relevant Doses

Paunovska, K., Da Silva Sanchez, A. J., Sago, C. D., Gan, Z., Lokugamage, M. P., Islam, F. Z., Kalathoor, S., Krupczak, B. R., & Dahlman, J. E. (2019) · Advanced Materials · doi:10.1002/adma.201807748 · Cited by 205

Strategies for nonviral nanoparticle‐based delivery of CRISPR/Cas9 therapeutics

Chen, F., Alphonse, M., & Liu, Q. (2020) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1609 · Cited by 197

Role of Lipid-Based and Polymer-Based Non-Viral Vectors in Nucleic Acid Delivery for Next-Generation Gene Therapy

Wahane, A. V., Waghmode, A., Kapphahn, A., Dhuri, K., Gupta, A., & Bahal, R. (2020) · Molecules · doi:10.3390/molecules25122866 · Cited by 202

Targeting of NLRP3 inflammasome with gene editing for the amelioration of inflammatory diseases

Xu, C., Lu, Z.-D., Luo, Y., Liu, Y., Cao, Z., Shen, S., Li, H., Liu, J., Chen, K., Chen, Z., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06522-5 · Cited by 199

Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): From bench to bedside

Bao, X., Liang, Y., Chang, H., Cai, T., Feng, B., Gordon, K., Zhu, Y., Shi, H., He, Y., & Xie, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01690-3 · Cited by 187

Rational designs of in vivo CRISPR-Cas delivery systems

Xu, C., Chen, G., Luo, Y., Zhang, Y., Zhao, G., Lu, Z.-D., Czarna, A., Gu, Z., & Wang, J. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.11.005 · Cited by 187

Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing

Zhang, X., Zhao, W., Nguyen, G. N., Zhang, C., Zeng, C., Yan, J., Du, S., Hou, X., Li, W., Jiang, J., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc2315 · Cited by 184

An engineered exosome for delivering sgRNA:Cas9 ribonucleoprotein complex and genome editing in recipient cells

Ye, Y., Zhang, X., Xie, F., Xu, B., Xie, P., Yang, T., Shi, Q., Zhang, C., Zhang, Y., Chen, J., et al. (2020) · Biomaterials Science · doi:10.1039/d0bm00427h · Cited by 184

Drug delivery systems for CRISPR-based genome editors

Madigan, V. J., Zhang, F., & Dahlman, J. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00762-x · Cited by 193

Non-liver mRNA Delivery

Loughrey, D., & Dahlman, J. E. (2022) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00601 · Cited by 173

Nanoscale platforms for messenger RNA delivery

Li, B., Zhang, X., & Dong, Y. (2019) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1530 · Cited by 170

Receptor-Mediated Delivery of CRISPR-Cas9 Endonuclease for Cell-Type-Specific Gene Editing

Rouet, R., Thuma, B. A., Roy, M. D., Lintner, N. G., Rubitski, D. M., Finley, J. E., Wisniewska, H. M., Mendonsa, R., Hirsh, A., de Oñate, L., et al. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b01551 · Cited by 163

Analyzing 2000 in Vivo Drug Delivery Data Points Reveals Cholesterol Structure Impacts Nanoparticle Delivery

Paunovska, K., Gil, C. J., Lokugamage, M. P., Sago, C. D., Sato, M., Lando, G. N., Gamboa Castro, M., Bryksin, A. V., & Dahlman, J. E. (2018) · ACS Nano · doi:10.1021/acsnano.8b03640 · Cited by 160

Biomaterial-assisted biotherapy: A brief review of biomaterials used in drug delivery, vaccine development, gene therapy, and stem cell therapy

Han, X., Alu, A., Liu, H., Shi, Y., Wei, X., Cai, L., & Wei, Y. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.01.011 · Cited by 165

CRISPR/Cas: Advances, Limitations, and Applications for Precision Cancer Research

Yang, Y., Xu, J., Ge, S., & Lai, L. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.649896 · Cited by 167

Triple‐Targeting Delivery of CRISPR/Cas9 To Reduce the Risk of Cardiovascular Diseases

Zhang, L., Wang, L., Xie, Y., Wang, P., Deng, S., Qin, A., Zhang, J., Yu, X., Zheng, W., & Jiang, X. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201903618 · Cited by 144

A Potent Branched-Tail Lipid Nanoparticle Enables Multiplexed mRNA Delivery and Gene Editing In Vivo

Hajj, K. A., Melamed, J. R., Chaudhary, N., Lamson, N. G., Ball, R. L., Yerneni, S. S., & Whitehead, K. A. (2020) · Nano Letters · doi:10.1021/acs.nanolett.0c00596 · Cited by 151

Non-viral delivery of the CRISPR/Cas system: DNA versus RNA versus RNP

Lin, Y., Wagner, E., & Lächelt, U. (2022) · Biomaterials Science · doi:10.1039/d1bm01658j · Cited by 148

Nanomedicine-Based Approaches for mRNA Delivery

Uchida, S., Perche, F., Pichon, C., & Cabral, H. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00618 · Cited by 139

Delivery of Tissue-Targeted Scalpels: Opportunities and Challenges for In Vivo CRISPR/Cas-Based Genome Editing

Wei, T., Cheng, Q., Farbiak, L., Anderson, D. G., Langer, R., & Siegwart, D. J. (2020) · ACS Nano · doi:10.1021/acsnano.0c04707 · Cited by 143

Nanomaterials for Therapeutic RNA Delivery

Han, X., Mitchell, M. J., & Nie, G. (2020) · Matter · doi:10.1016/j.matt.2020.09.020 · Cited by 139

Nanoplatforms for mRNA Therapeutics

Meng, C., Chen, Z., Li, G., Welte, T., & Shen, H. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000099 · Cited by 130

Biomedical applications of mRNA nanomedicine

Xiong, Q., Lee, G. Y., Ding, J., Li, W., & Shi, J. (2018) · Nano Research · doi:10.1007/s12274-018-2146-1 · Cited by 125

mRNA therapeutics deliver a hopeful message

Zhong, Z., Cafferty, S. M., Combes, F., Huysmans, H., Temmerman, J. D., Gitsels, A., Vanrompay, D. C. G., Catani, J. P., & Sanders, N. N. (2018) · Nano Today · doi:10.1016/j.nantod.2018.10.005 · Cited by 124

Material solutions for delivery of CRISPR/Cas-based genome editing tools: Current status and future outlook

Wan, T. Y., Niu, D., Wu, C., Xu, F., Church, G. M., & Yuan, P. (2019) · Materials Today · doi:10.1016/j.mattod.2018.12.003 · Cited by 119

CRISPR/Cas9 Genome-Editing System in Human Stem Cells: Current Status and Future Prospects

Zhang, Z., Zhang, Y., Gao, F., Han, S., Cheah, K. S. E., Tse, H., & Lian, Q. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.09.009 · Cited by 122

Non-Viral Delivery To Enable Genome Editing

Rui, Y., Wilson, D. R., & Green, J. J. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2018.08.010 · Cited by 115

Systemic mRNA delivery to the lungs by functional polyester-based carriers

Yan, Y., Xiong, H., Zhang, X., Cheng, Q., & Siegwart, D. J. (2017) · Biomacromolecules · doi:10.1021/acs.biomac.7b01356 · Cited by 111

Carrier strategies boost the application of CRISPR/Cas system in gene therapy

Xu, Z., Wang, Q., Zhong, H., Jiang, Y., Shi, X., Yuan, B., Yu, N., Zhang, S., Yuan, X., Guo, S., et al. (2022) · Exploration · doi:10.1002/exp.20210081 · Cited by 105

Tropism-facilitated delivery of CRISPR/Cas9 system with chimeric antigen receptor-extracellular vesicles against B-cell malignancies

Xu, Q., Zhang, Z., Zhao, L., Qin, Y., Cai, H., Geng, Z., Zhu, X., Zhang, W., Zhang, Y., Tan, J., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.033 · Cited by 106

Overcoming the delivery problem for therapeutic genome editing: Current status and perspective of non-viral methods

Mashel, T. V., Tarakanchikova, Y. V., Muslimov, A. R., Zyuzin, M. V., Timin, A. S., Lepik, K. V., & Fehse, B. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120282 · Cited by 102

Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease

Ernst, M. P. T., Broeders, M., Herrero-Hernandez, P., Oussoren, E., van der Ploeg, A. T., & Pijnappel, W. W. M. P. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.06.022 · Cited by 103

Targeted delivery of CRISPR interference system against Fabp4 to white adipocytes ameliorates obesity, inflammation, hepatic steatosis, and insulin resistancePreprint

Chung, J. Y., Ain, Q. U., Song, Y., Yong, S., & Kim, Y. (2019) · Genome Research · doi:10.1101/gr.246900.118 · Cited by 102

Cell-Selective Messenger RNA Delivery and CRISPR/Cas9 Genome Editing by Modulating the Interface of Phenylboronic Acid-Derived Lipid Nanoparticles and Cellular Surface Sialic Acid

Tang, Q., Liu, J., Jiang, Y. Y., Zhang, M., Mao, L., & Wang, M. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b17749 · Cited by 99

GMOs or non-GMOs? The CRISPR Conundrum

Ahmad, A., Jamil, A., & Munawar, N. (2023) · Frontiers in Plant Science · doi:10.3389/fpls.2023.1232938 · Cited by 114

Non-viral Delivery of Zinc Finger Nuclease mRNA Enables Highly Efficient In Vivo Genome Editing of Multiple Therapeutic Gene Targets

Conway, A., Mendel, M., Kim, K., McGovern, K., Boyko, A., Zhang, L., Miller, J. C., DeKelver, R. C., Paschon, D. E., Mui, B. L., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.03.003 · Cited by 95

Modification of Lipid-Based Nanoparticles: An Efficient Delivery System for Nucleic Acid-Based Immunotherapy

Zhang, C., Ma, Y., Zhang, J., Kuo, J. C., Zhang, Z., Xie, H., Zhu, J., & Liu, T. (2022) · Molecules · doi:10.3390/molecules27061943 · Cited by 95

Next-Generation CRISPR Technologies and Their Applications in Gene and Cell Therapy

C., M. A. Z., & Gaj, T. (2020) · Trends in biotechnology · doi:10.1016/j.tibtech.2020.10.010 · Cited by 99

The Promise and Challenge of In Vivo Delivery for Genome Therapeutics

Wilson, R. C., & Gilbert, L. A. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00680 · Cited by 98

Theranostic dendrimer-based lipid nanoparticles containing PEGylated BODIPY dyes for tumor imaging and systemic mRNA delivery in vivo

Xiong, H., Liu, S., Wei, T., Cheng, Q., & Siegwart, D. J. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.06.030 · Cited by 92

Engineering nanoparticle toolkits for mRNA delivery

Sun, B., Wu, W., Narasipura, E. A., Ma, Y., Yu, C., Fenton, O. S., & Song, H. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115042 · Cited by 96

Lipid nanoparticle (LNP) mediated mRNA delivery in cardiovascular diseases: Advances in genome editing and CAR T cell therapy

Soroudi, S., Jaafari, M. R., & Arabi, L. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.06.023 · Cited by 96

Biomaterials as vectors for the delivery of CRISPR–Cas9

Eoh, J. H., & Gu, L. (2019) · Biomaterials Science · doi:10.1039/c8bm01310a · Cited by 92

Design concepts of polyplex micelles for in vivo therapeutic delivery of plasmid DNA and messenger RNA

Uchida, S., & Kataoka, K. (2019) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.36614 · Cited by 90

Lipid Polymer Hybrid Nanomaterials for mRNA Delivery

Zhao, W., Zhang, C., Li, B., Zhang, X., Luo, X. L., Zeng, C., Li, W., Gao, M., & Dong, Y. (2018) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-018-0536-9 · Cited by 86

Testing thousands of nanoparticles in vivo using DNA barcodes

Lokugamage, M. P., Sago, C. D., & Dahlman, J. E. (2018) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2018.08.001 · Cited by 84

Spatiotemporal Delivery of CRISPR/Cas9 Genome Editing Machinery Using Stimuli‐Responsive Vehicles

Cai, W., Luo, T., Mao, L., & Wang, M. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202005644 · Cited by 83

RNA delivery biomaterials for the treatment of genetic and rare diseases

Zhao, W., Hou, X., Vick, O. G., & Dong, Y. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119291 · Cited by 82

Harnessing nanoparticles for the efficient delivery of the CRISPR/Cas9 system

Rahimi, H., Salehiabar, M., Charmi, J., Barsbay, M., Ghaffarlou, M., Razlighi, M. R., Davaran, S., Khalilov, R. I., Sugiyama, M., Nosrati, H., et al. (2020) · Nano Today · doi:10.1016/j.nantod.2020.100895 · Cited by 83

Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing

Sinclair, F., Begum, A. A., Dai, C. C., Tóth, I., & Moyle, P. M. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-023-01320-z · Cited by 91

Advanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular Carcinoma

Kong, H., Ju, E., Yi, K., Xu, W., Lao, Y., Cheng, D., Zhang, Q., Tao, Y., Li, M., & Ding, J. (2021) · Advanced Science · doi:10.1002/advs.202102051 · Cited by 77

CRISPR/Cas9 Genome Editing for Tissue‐Specific In Vivo Targeting: Nanomaterials and Translational Perspective

Sahel, D. K., Vora, L. K., Saraswat, A. L., Sharma, S., Monpara, J. D., D’souza, A. A., Mishra, D., Tryphena, K. P., Kawakita, S., Khan, S. U., et al. (2023) · Advanced Science · doi:10.1002/advs.202207512 · Cited by 79

An antifouling membrane-fusogenic liposome for effective intracellular delivery in vivo

Kong, H., Zheng, C., Yi, K., Mintz, R. L., Lao, Y., Tao, Y., & Li, M. (2024) · Nature Communications · doi:10.1038/s41467-024-46533-z · Cited by 80

Small molecules as inhibitors of PCSK9: Current status and future challenges

Xu, S., Luo, S., Zhu, Z., & Xu, J. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.011 · Cited by 85

Synthetic multi-layer nanoparticles for CRISPR-Cas9 genome editing

Tang, H., Zhao, X., & Jiang, X. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.03.001 · Cited by 80

Fluorinated Acid‐Labile Branched Hydroxyl‐Rich Nanosystems for Flexible and Robust Delivery of Plasmids

Yu, Q., Song, H., Xiao, H., Cheng, G., Yu, B., & Xu, F. (2018) · Small · doi:10.1002/smll.201803061 · Cited by 75

Gene Therapy for Chronic HBV—Can We Eliminate cccDNA?

Bloom, K. M., Maepa, M. B., Ely, A., & Arbuthnot, P. B. (2018) · Genes · doi:10.3390/genes9040207 · Cited by 76

Targeted lipid nanoparticles for RNA therapeutics and immunomodulation in leukocytes

Veiga, N., Diesendruck, Y., & Peer, D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.04.002 · Cited by 78

Augmented lipid-nanoparticle-mediated in vivo genome editing in the lungs and spleen by disrupting Cas9 activity in the liver

Sago, C. D., Lokugamage, M. P., Loughrey, D., Lindsay, K. E., Hincapie, R., Krupczak, B. R., Kalathoor, S., Sato, M., Echeverri, E. S., Fitzgerald, J. P., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00847-9 · Cited by 75

Poly(Beta-Amino Ester) Nanoparticles Enable Nonviral Delivery of CRISPR-Cas9 Plasmids for Gene Knockout and Gene Deletion

Rui, Y., Varanasi, M., Mendes, S., Yamagata, H. M., Wilson, D. R., & Green, J. J. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.04.005 · Cited by 71

Inhibition of hepatitis B virus replication via HBV DNA cleavage by Cas9 from Staphylococcus aureus

Liu, Y., Zhao, M., Gong, M., Xu, Y., Xie, C., Deng, H., Li, X., Wu, H., & Wang, Z. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.02.011 · Cited by 71

A Dual-Targeting Delivery System for Effective Genome Editing and In Situ Detecting Related Protein Expression in Edited Cells

Liu, B., He, X., Xu, C., Xu, L., Ai, S., Cheng, S., & Zhuo, R. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.8b00511 · Cited by 68

Nanotechnology based CRISPR/Cas9 system delivery for genome editing: Progress and prospect

Deng, H., Huang, W., & Zhang, Z. (2019) · Nano Research · doi:10.1007/s12274-019-2465-x · Cited by 70

Harnessing lipid nanoparticles for efficient CRISPR delivery

Yan, J., Kang, D. D., & Dong, Y. (2021) · Biomaterials Science · doi:10.1039/d1bm00537e · Cited by 69

Therapeutic potentials of CRISPR-Cas genome editing technology in human viral infections

Najafi, S., Tan, S. C., Aghamiri, S., Raee, P., Ebrahimi, Z., Jahromi, Z. K., Rahmati, Y., Nahand, J. S., Piroozmand, A., Jajarmi, V., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112743 · Cited by 69

Evolving AAV-delivered therapeutics towards ultimate cures

He, X., Urip, B. A., Zhang, Z., Ngan, C. C., & Feng, B. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-020-02034-2 · Cited by 70

CRISPR/Cas9 for Sickle Cell Disease: Applications, Future Possibilities, and Challenges

Demirci, S., Leonard, A., Haro-Mora, J. J., Uchida, N., & Tisdale, J. F. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2018_331 · Cited by 50

Engineered Nanomaterials to Potentiate CRISPR/Cas9 Gene Editing for Cancer Therapy

Yi, K., Kong, H., Lao, Y., Li, D., Mintz, R. L., Fang, T., Chen, G., Tao, Y., Li, M., & Ding, J. (2023) · Advanced Materials · doi:10.1002/adma.202300665 · Cited by 66

Proteomic profiling of HIV-1 infection of human CD4+ T cells identifies PSGL-1 as an HIV restriction factor

Liu, Y., Fu, Y., Wang, Q., Li, M., Zhou, Z., Dabbagh, D., Fu, C., Zhang, H., Li, S., Zhang, T., et al. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0372-2 · Cited by 64

Delivery of CRISPR/Cas9 by Novel Strategies for Gene Therapy

Wang, L., Zheng, W., Liu, S., Li, B. J., & Jiang, X. (2018) · ChemBioChem · doi:10.1002/cbic.201800629 · Cited by 66

Non-viral strategies for delivering genome editing enzymes

Li, J., Røise, J. J., He, M., Das, R., & Murthy, N. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.09.004 · Cited by 63

Spatial and Temporal Control of CRISPR-Cas9-Mediated Gene Editing Delivered via a Light-Triggered Liposome System

Aksoy, Y. A., Yang, B., Chen, W., Hung, T., Kuchel, R. P., Zammit, N. W., Grey, S. T., Goldys, E. M., & Deng, W. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c16380 · Cited by 63

Optimization of lipid nanoparticles loaded with ribonucleoprotein-oligonucleotide complexes for in vivo delivery of a CRISPR/Cas9 system targeting hepatitis B virus

Akhter, R., Kitab, B., Kayesh, M. E. H., Shimizu, R., Onuma, H., Yamamoto, N., Ogawa, S., Sugiyama, M., Tanaka, Y., Sato, Y., et al. (2025) · Virus Research · doi:10.1016/j.virusres.2025.199682 · Cited by 1

Development of an in vivo delivery system for CRISPR/Cas9-mediated targeting of hepatitis B virus cccDNA

Kayesh, M. E. H., Amako, Y., Hashem, M. A., Murakami, S., Ogawa, S., Yamamoto, N., Hifumi, T., Miyoshi, N., Sugiyama, M., Tanaka, Y., et al. (2020) · Virus Research · doi:10.1016/j.virusres.2020.198191 · Cited by 39

In vivo Delivery Tools for Clustered Regularly Interspaced Short Palindromic Repeat/Associated Protein 9-Mediated Inhibition of Hepatitis B Virus Infection: An Update

Kayesh, M. E. H., Hashem, M. A., Kohara, M., & Tsukiyama–Kohara, K. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.953218 · Cited by 4

Preparation of nanoparticles for hepatitis B viral therapy

Kružíková, Z. (2018) · Digital Repository (National Repository of Grey Literature)

CRISPR-Cas9 System In Vivo Delivery to Combat HBV

Ali, J., Aslam, H., & Yousuf, A. (2023) · BIOEDUSCIENCE · doi:10.22236/jbes/12693 · Cited by 1